Pharma and biotech teams invest significant time and resource into Integrated Evidence Generation Plans (IEGPs). But having a plan — and having one that’s resilient to policy shifts, aligned across functions, and decision-relevant in every key market — are two very different things.
At ISPOR 2026, our experts explored exactly this challenge. The recording is now available to watch on demand — and if evidence strategy is on your agenda, it’s 30 minutes well spent.
What the session covers
The session walks through the full IEGP lifecycle, from understanding the existing evidence base to identifying and prioritizing evidence gaps — and highlights where HEOR & RWE should be guiding evidentiary priorities at every step.
It also digs into three high-impact pitfalls we see in real-world IEGPs:
1. Siloed working
Function-led planning consistently sidelines HEOR and RWE until after key evidence decisions are made. The session outlines how to establish HEOR/RWE-led, cross-functional governance before it’s too late.
2. Global-to-local misalignment
Global-first IEGPs routinely miss country-specific requirements — from US IRA timelines to EU JCA evidence expectations. The fix: modular plans informed by local intelligence from the outset.
3. Visibility and usability
An IEGP that gets consulted only at submission isn’t a strategy — it’s a retrospective document. The session sets out how to operationalize a visible, durable working plan used throughout the lifecycle.
Watch the recording
"*" indicates required fields
